– FDCA Mass Production Moves Forward to Origin 2, Rather Than Origin 3 as Initially Planned, Due to Strong Commercialization Progress and Higher-Margin Opportunities – – Origin 2 Outlook Updated ...

Origin Bancorp, Inc. will release its second quarter 2025 financial results on July 23, 2025, after market closure, followed by a conference call on July 24, 2025, at 8:00 a.m. Central Time. The ...

– Announces Review of Strategic Opportunities and New Market Segmentation to Accelerate Value Capture – – Revises Revenue and Run-Rate Adjusted EBITDA Guidance – WEST SACRAMENTO, Calif.--(BUSINESS ...

– Origin 1 Construction Timeline On Track and Capital Budget Unchanged – – Origin 2 Construction Timeline, Budget, and Financing Unchanged – – Customer Demand is Strong and Broad Based, Increased ...

Vera Therapeutics, Inc. announced that its ORIGIN Phase 3 trial for atacicept, a treatment for immunoglobulin A nephropathy (IgAN), achieved its primary endpoint by demonstrating a significant ...

– Announces Signed Strategic Customer Agreement with Major Packaging Company for the Development of Large Format PET Closures for the Ready to Drink, Wine, and Spirits Market – – Over Twenty Companies ...